Biomunex CEO on earlier deals for cancer drugs

April 11, 2017 Christoph Graener

During the recent BIO-Europe Spring partnering conference in Barcelona, Biomunex CEO Pierre-Emmanuel Gerard chats with Scrip about the company’s strategy for partnering with pharmas in the cancer drug development space. He also comments on the recent trend of companies seeking earlier stage deals in cancer drug development and the benefits of this approach for both smaller biotechs and their larger pharma partners.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Pierre-Emmanuel Gerard – CEO, Biomunex

Previous Article
Biomunex CSO defines lead compounds, early R&D plans

Eugene Zhukovsky, CSO at Biomunex, talks about the company's clinical development strategy of using monospe...

Next Article
Digimed and diagnostics: Market access and new collaborations

The effect of digital medicine on diagnostics is having and will continue to have a revolutionary effect on...